Thanks to advances made possible by clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace. As a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The fact is, patients in studies receive either the best treatment currently known for their specific cancer, or a new and possibly more effective therapy. Placebos are never used in place of treatment when an existing therapy exists.

The Latest Advances in the Fight Against Cancer

The Ann B. Barshinger Cancer Institute has a clinical research department that keeps our team apprised of the latest advances in research, including new and promising therapies that are on the horizon, and clinical trials that may benefit our patients.

Our team includes a regulatory specialist and clinical research nurses who participate in tumor boards (multidisciplinary meetings at which cases and treatment options are reviewed) and work closely with the physicians to identify patients who might meet the criteria for a clinical study. The nurses also help patients navigate the process of screening for and participating in clinical trials, providing education and support, symptom management, and care coordination throughout the duration of the study.

The Cancer Institute takes part in large, national studies sponsored by the National Cancer Institute through groups such as the Eastern Cooperative Oncology Group, the Radiation Therapy Oncology Group and the American College of Surgeons Oncology Group. We also collaborate with our colleagues at the Abramson Cancer Center to identify any studies taking place in Philadelphia that may be a good fit for our patients.

Current Oncology Clinical Trials

Current oncology treatment trials open for participation include:

Site of Cancer: Breast

  • CREP-Penn—Familial Breast Cancer Studies
  • PROMPT-Penn—Prospective Registry of MultiPlex Testing
  • METAMORPH-Penn—Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
  • ImPASSION030 AFT/Genentech—A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (ANTI-PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy versus Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer

Site of Cancer: Gastric

  • SPOTLIGHT: 8951-CL-0301 ASTELLAS—Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus MFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Site of Cancer: Renal

  • Entrata: CX-839-005 Calitheria—A Randomized, Double-blind, Placebo-Controlled Phase 2 Study Comparing  CB-839 in Combination with Everolimus (CBE) vs. Placebo with Everolimus (PboE) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Site of Cancer: Ovarian

  • NRG-GY009—A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin And CTEP-Supplied Atezolizumab (IND#134427) Versus Pegulated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Site of Cancer: Hematology

  • Connect MDS and AML AZA-MDS-006 Celgene—The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • STOP-CA-Penn—Statins TO Prevent the Cardiotoxicity from Anthracyclines


  • EAY131-MATCH ECOG—Molecular Analysis for Therapy Choice (MATCH)
Share This Page: